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The course of asthma during pregnancy 
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Abstract 
Background: Over the years it has been widely stated that approximately one-third of asthmatic women experience 
worsening of the disease during pregnancy. However, the literature has not been reviewed systematically and the 
meta-analytic reviews include old studies. This study aimed to examine whether the prevalence of worsening asthma 
during pregnancy is still consistent with prior estimate or it has been reduced.
Methods: A detailed Clinical Questionnaire on respiratory symptoms, medical history, medication, use of services, 
occupation, social status, home environment and lifestyle was administered to random samples of the Italian popu-
lation in the frame of the Gene Environment Interactions in Respiratory Diseases (GEIRD) study. Only clinical data 
belong to 2.606 subjects that completed the clinical stage of the GEIRD study, were used for the present study.
Results: Out of 1.351 women, 284 self-reported asthma and 92 of them had at least one pregnancy. When we 
considered the asthma course during pregnancy, we found that 16 women worsened, 31 remained unchanged, 
25 improved. Seven women had not the same course in the different pregnancies and 13 did not know. The start-
ing age of ICS use almost overlaps with that of asthma onset in women with worsening asthma during pregnancy 
(19 years ± 1.4), unlike the other women who started to use ICS much later (30.3 years ± 12). In addition, the wors-
ening of asthma was more frequent in women with an older age of onset of asthma (18 years ± 9 vs 13 years ± 10). 
Among women who completed the ACT during the clinical interview, the 50% of women who experienced worsen-
ing asthma during pregnancy (6/12) had an ACT score below 20.
Conclusion: Asthma was observed to worsen during pregnancy in a percentage much lower to that generally 
reported in all the previous studies. There is still room in clinical practice to further reduce worsening of asthma 
during pregnancy by improving asthma control, with a more structured approach to asthma education and manage-
ment prepregnancy.
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Background
Asthma is the most common respiratory disorder com-
plicating pregnancy and it is associated with a range of 
adverse maternal and perinatal outcomes. Its prevalence 
among pregnant women varies among studies from 4 to 
8% and appears to have increased over recent decades. 
Several studies have demonstrated that the use of inhaled 
corticosteroid (ICS) for the treatment of asthma does 
not affect fetal growth, and that maternal uncontrolled 
asthma has a greater impact on the fetus and placenta [1–
3]. Even though asthma is a potentially serious medical 
condition and despite known risks of poorly controlled 
asthma during pregnancy, a large proportion of women 
still have a sub-optimal asthma control, principally due 
to concerns about surrounding risks of pharmacologi-
cal agents, particularly ICS, and uncertainties regarding 
the effectiveness and the safety of different management 
strategies.
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The course of asthma during pregnancy, evaluated in 
numerous retrospective and prospective studies over the 
years, has resulted to be variable. It has been stated that 
about one-third of asthmatic women experience worsen-
ing of the disease during pregnancy [4–7]. However, the 
literature has not been reviewed systematically and the 
meta-analytic reviews include old studies that vary in 
population characteristics such as asthma severity and 
treatment received. Many of these old studies have sev-
eral methodologic inadequacy, such as low power or lack 
of control for confounders.
While a number of factors that may worsen asthma 
have been proposed in the literature, the mechanisms 
involved are largely undefined, and thus a woman’s 
asthma course during pregnancy is often unpredictable 
[8].
The aim of our study was to examine whether the 
prevalence of worsening asthma during pregnancy is still 
consistent with prior estimates or it has been reduced. 
For this purpose, we used data of our population-based 
Gene-Environment Interactions in Respiratory Disease 
(GEIRD) study.
Methods
Study design
GEIRD is a multicase–control study on respiratory 
health, involving seven Italian centres. Cases and controls 
were identified through a two-stage screening process in 
pre-existing cohorts and in new random samples from 
the Italian general population.
In the first stage (2007–2010), eligible subjects were 
administered a screening questionnaire on respira-
tory symptoms. In the second stage (2008–2016) all the 
responders with symptoms suggestive of asthma, chronic 
obstructive pulmonary disease (COPD) or chronic bron-
chitis (CB) and a random sample of subjects without 
respiratory symptoms or with symptoms suggestive of 
rhinitis, were referred to clinical centres to undergo the 
“phenotypization” protocol. Protocol and descriptive 
characteristics of the GEIRD study are available on the 
web site http://www.geird.org [9].
Study population and procedures
For the present study we used clinical data belonging to 
2606 subjects, who completed the stage 2 of the GEIRD 
study. Clinical data were obtained by means of a struc-
tured medical interview through the Clinical Ques-
tionnaire, a modification of the European Community 
Respiratory Health Survey (ECRHS) questionnaire 
(http://www.ecrhs.org) including detailed questions on 
respiratory symptoms, medical history, medication, use 
of services, occupation, social status, home environment 
and lifestyle. For the evaluation of regular ICS use and 
patient adherence to anti-asthmatic treatment the ques-
tions: “Since the last survey have you used inhaled corti-
costeroids?”, “How old were you when you first started to 
use inhaled corticosteroids?”, “Have you used inhaled cor-
ticosteroids every year since the last survey?”, “If you are 
prescribed medicines for your breathing, do you normally 
take: A) all of the medicines? B) most of the medicines? 
C) some of the medicines? D) none of the medicines” were 
used [10].
On the basis of the answers to the Clinical Question-
naire, a woman was considered to have asthma if she 
answered affirmatively to both questions: “Have you ever 
had asthma?” and ‘‘Was this confirmed by a doctor?’’.
The asthma course during pregnancy was evaluated 
with the specific question: “What happened to your 
asthma during your pregnancies? A) got better B) got 
worse C) stayed the same D) not the same for all pregnan-
cies E) don’t know”.
Participants were considered to have allergic rhinitis if 
they answered positively to this question: “Do you have 
any nasal allergies including hay fever?”.
Atopy was assessed by skin prick tests (SPT). Indi-
viduals with at least one positive SPT were considered 
to be atopic. The allergens selected in all centres were 
Cupressus arizonica, Graminacee mix Dermatophagoi-
des pteronyssinus, Artemisia vulgaris, Dermatophagoides 
farina, Ambrosia artemisifolia, Alternaria tenuis, Pari-
etaria Judaica, Dog dander, Corylus avellana, Cat hair, 
Olea europea, Betula verrucosa, Cladosporium herbarum 
(ALK diagnostics, Denmark) (Mailing 1993).
In a subsample of 50 asthmatic women, we also evalu-
ated the asthma control by means of the Asthma Control 
Test (ACT™). Patients assigned scores of 1–5 to each 
item, resulting in the following grading system: uncon-
trolled/partly controlled asthma with score ≤ 20; well 
controlled asthma with score > 20 [11]. These data refer to 
the time of the clinical interview and they cannot be used 
as an indicator of asthma control before pregnancy.
No clinical data before pregnancy are available.
Statistical analysis
Women who answered “D) not the same (asthma) for all 
pregnancies” were excluded from the statistical analyses. 
The sample who answered “E) don’t know” was included 
in the group of those unchanged/improved asthma. The 
relationship of the main determinants of unchanged/
improved asthma during pregnancy and worsened 
asthma during pregnancy was evaluated by Fisher’s exact 
test for categorical variables and by Wilcoxon–Mann–
Whitney non-parametric test for continuous variables. 
The statistical analyses were performed using Stata 14.0 
(StataCorp, College Station, TX, USA).
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Results
Out of 1351 women, 284 (mean age 44.4 ± 9) self-
reported asthma and 92 of them had at least one 
pregnancy.
When we considered the asthma course during preg-
nancy, we found that 16 women worsened, 31 remained 
unchanged, 25 improved. Seven women had not the same 
course in the different pregnancies and 13 did not know.
Table 1 reports the results of the associations between 
considered factors and outcomes in the univariate analy-
sis. Women who reported that the asthma was different 
from pregnancy to pregnancy were removed from the 
statistical analysis, because it was not possible to include 
it in either group, as there is no information on the num-
ber of pregnancies and on the course of asthma during 
each pregnancy. Instead, the sample who answered “don’t 
know” was included in the group of those “improved” or 
“unchanged” (N = 69). The reason is related to the fact 
that those who have no memory for a negative condi-
tion, most likely did not experience it. The worsening 
of asthma during pregnancy was significantly associ-
ated with a more regular use of ICS (p < 0.05). The start-
ing age of ICS use almost overlaps with that of asthma 
onset in women with worsening asthma during preg-
nancy (19  years ± 1.4), unlike the other women who 
started to use ICS much later (30.3 years ± 12). In addi-
tion, the worsening of asthma was more frequent in 
women with an older age of onset of asthma (18 years ± 9 
vs 13  years ± 10). Among 50 women who completed 
the ACT during the clinical interview, 16 (32%) showed 
uncontrolled/partially controlled asthma (score < 20). In 
particular, 50% of women who experienced worsening 
asthma during pregnancy (6/12) had ACT score below 
20, versus 26% of those with no worsening asthma dur-
ing pregnancy (“unchanged”/“improved”/“don’t know” 
group). The percentage of women with a good treatment 
adherence was found to be higher in those with worsen-
ing asthma during pregnancy than in the other group, 
even if the difference was not statistically significant 
(respectively 92 and 81%).
When we considered smoking habits, BMI, presence 
of atopy and rhinitis, no statistically significant differ-
ence between the two groups was found in the univariate 
analysis.
Discussion
The main finding in the present analysis is that asthma 
was observed to worsen during pregnancy in a percent-
age much lower that the one generally reported in all 
the previous studies, 18.8% (16/85) versus 30%. A meta-
analytic review of 14 studies, conducted before 1990, 
assessing changes in the course of asthma throughout 
pregnancy suggested that approximately one-third of 
pregnant asthmatic women experience a symptomatic 
improvement, one-third experience a worsening, and 
one-third remain the same [12]. In our knowledge, at 
present, there are only few published data recently col-
lected and the use of heterogeneous methods, such as 
the subjective nature and different definitions of asthma 
symptoms and control, makes the comparison with the 
older studies difficult.
The worsening of asthma during pregnancy repre-
sented an important problem in the management of the 
disease, taking into account the increased risk for pre-
term delivery, low birth weight preeclampsia and Cesar-
ean delivery. Some studies indicated that over one-third 
of women may discontinue their asthma medications 
during pregnancy, many without consulting their doctors 
and that only half of the pregnant women with asthma 
used their controller drugs regularly during pregnancy 
Table 1 Characteristics of women with worsened asthma 
and women with not worsened asthma during pregnancy
Significant p value is highlighted in italic (p < 0.05)
ICS, inhaled corticosteroid; BMI, body mass index; p, values compared between 
groups
Characteristics “Not worsened” 
asthmatics
(n = 69)
“Worsened” asth-
matics
(n = 16)
p
Smoking status, n (%)
 Current smoker 13 (18.8) 3 (18.8) 1.0
 Former/never 
smoker
56 (81.2) 13 (81.2)
BMI category (kg/m2), n (%)
 < 18.5 3 (4.5) 0 (0.0) 0.710
 18.5–24 44 (65.7) 12 (75.0)
 25–29 14 (2.9) 4 (25.0)
 > 30 6 (8.9) 0 (0.0)
Asthmatic treatment adherence category, n (%)
 Null/poor 7 (19.0) 1 (7.7) 0.662
 High/moderate 30 (81.4) 12 (92.3)
Age of asthma onset (year), mean ± SD
13.3 ± 10.2 18.2 ± 9.5 0.09
Allergic rhinitis, n (%)
 No 14 (21.5) 3 (20.0) 0.602
 Yes 51 (78.5) 12 (80.0)
Atopy, n (%)
 No 10 (15.4) 2 (13.0) 0.602
 Yes 55 (84.6) 13 (87.0)
Starting age of anti-asthmatic drug use (year), mean ± SD
22.3 ± 15 19.3 ± 10.0 0.553
Starting age of ICS use (year), mean ± SD
30.3 ± 12 19 ± 1.4 0.2465
Regular ICS use, n (%)
 No 49 (71.0) 7 (44.0)  0.046
 Yes 20 (29.0) 9 (56.0)
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[13, 14]. The undermedication of pregnant women with 
asthma may contribute to worsening of asthma symp-
toms in some women during pregnancy [15].
Over the past 20  years, there was an evolving under-
standing of heterogeneous airways disease, a broader 
evidence base, increasing interest in targeted treatment, 
and evidence about effective implementation approaches. 
Substantial advances have been made in knowledge 
about a wide range of new effective therapies and under-
standing of many important aspects of asthma care. In 
the past medication would not have included inhaled 
corticosteroids, which are a mainstay of treatment today. 
Inhaled corticosteroids are the treatment of choice for all 
levels of persistent asthma and asthma guidelines around 
the world strongly recommend that women continue 
their asthma medications during pregnancy to maintain 
adequate control [13].
It has been well documented that the course of asthma 
during pregnancy may be influenced by the various phys-
iologic changes during pregnancy, as well as the sever-
ity of the pre-existing disease and that in general after 
delivery, asthma returns to the severity that was present 
before pregnancy [6, 7, 16, 17]. Our results indirectly 
confirm the influence of the severity of the disease in the 
asthma worsening that was present despite a more fre-
quent regular use of ICS and a higher treatment adher-
ence. A further confirmation comes from the result of a 
low ACT score in the subsample of 50 women.
Also, the age of asthma onset was higher in this group 
than in the other and it is well known that adult-onset 
asthma has a low remission rate, a worse prognosis and 
a poorer response to standard asthma treatment [18]; in 
general, asthma in adult-onset usually relates with severe 
types of the disease. The concomitant presence of rhi-
nitis worsens the asthma control in these subjects, as 
shown by the Rhinasthma’s score. The score was on aver-
age higher in asthmatics who reported worsening of the 
disease (31.36 ± 25.92), although the difference with the 
comparison group was not significant, probably because 
of the small number of cases. Differently from Grzeskow-
iak et  al. no influence of smoking habits and BMI on 
worsening asthma during pregnancy was found in our 
sample.
Strengths and limits of the study
Strengths of our study include the use of data recently 
collected from more than 1300 women randomly drawn 
from the general population rather than from clinically 
selected groups, the collection of high quality data, the 
standardized questionnaires and protocol procedures. 
Nonetheless, our study has several limitations. The first 
weakness is the relatively limited number of cases, which 
also precludes the multivariate analysis on the factors 
associated with the worsening of asthma during preg-
nancy. Another important limitation is that we fully rely 
on self-reported data. In addition, we have only data on 
asthma control and on use of ICS referred to the time of 
the clinical interview and not those before pregnancy.
Conclusion
The most interesting findings of this study are that: (1) 
the prevalence of asthma worsening during pregnancy is 
actually reduced compared to the past and (2) the wors-
ening is significantly related to the severity of the disease, 
as indicated by the more regular use of ICS and by the 
presence of an ACT score below 20. There is still room 
in clinical practice to further reduce worsening of asthma 
during pregnancy by improving asthma control, with a 
more structured approach to asthma education and man-
agement pre-pregnancy.
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